Ionis Pharmaceuticals (NASDAQ:IONS) Announces Earnings Results, Beats Expectations By $0.46 EPS

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) released its earnings results on Wednesday. The company reported ($0.66) EPS for the quarter, topping analysts' consensus estimates of ($1.12) by $0.46, RTT News reports. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The company had revenue of $227.00 million for the quarter, compared to the consensus estimate of $140.97 million. During the same quarter last year, the business posted $0.12 EPS. Ionis Pharmaceuticals's quarterly revenue was down 30.2% compared to the same quarter last year. Ionis Pharmaceuticals updated its FY 2025 guidance to EPS.

Ionis Pharmaceuticals Price Performance

Shares of IONS stock traded down $0.36 during mid-day trading on Friday, hitting $32.33. 1,569,929 shares of the stock traded hands, compared to its average volume of 1,708,983. Ionis Pharmaceuticals has a twelve month low of $30.23 and a twelve month high of $52.34. The firm has a market cap of $5.14 billion, a price-to-earnings ratio of -10.63 and a beta of 0.34. The company's 50-day simple moving average is $33.65 and its 200-day simple moving average is $38.36. The company has a debt-to-equity ratio of 2.12, a quick ratio of 8.82 and a current ratio of 8.47.

Insider Buying and Selling

In other Ionis Pharmaceuticals news, Director Michael R. Hayden bought 5,000 shares of the firm's stock in a transaction dated Monday, December 23rd. The stock was acquired at an average price of $36.22 per share, with a total value of $181,100.00. Following the completion of the transaction, the director now directly owns 35,219 shares in the company, valued at approximately $1,275,632.18. This represents a 16.55 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Patrick R. O'neil sold 6,165 shares of the firm's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $31.62, for a total value of $194,937.30. Following the completion of the sale, the executive vice president now directly owns 57,452 shares of the company's stock, valued at approximately $1,816,632.24. This trade represents a 9.69 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 110,609 shares of company stock worth $3,564,867 in the last three months. 2.71% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

IONS has been the topic of a number of research analyst reports. Citigroup reduced their target price on Ionis Pharmaceuticals from $67.00 to $64.00 and set a "buy" rating on the stock in a report on Thursday. Wells Fargo & Company cut their price target on Ionis Pharmaceuticals from $82.00 to $77.00 and set an "overweight" rating on the stock in a report on Thursday, November 7th. Royal Bank of Canada reissued an "outperform" rating and issued a $70.00 price target on shares of Ionis Pharmaceuticals in a report on Thursday. Needham & Company LLC reissued a "buy" rating and issued a $60.00 price target on shares of Ionis Pharmaceuticals in a report on Thursday. Finally, William Blair reissued an "outperform" rating on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Ionis Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $60.00.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.